<DOC>
	<DOC>NCT00612911</DOC>
	<brief_summary>Using bone marrow mononuclear cell in 24 patients with Idiopathic dilated cardiomyopathy</brief_summary>
	<brief_title>Cell Therapy in Dilated Cardiomyopathy: Observational Study</brief_title>
	<detailed_description>Patients with Idiopathic dilated cardiomyopathy class II to IV NYHA with ejection fraction &lt;35% were selected for phase I clinical trial of bone marrow mononuclear cell delivery in the coronary arteries and followed for 6 months</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy, Dilated</mesh_term>
	<criteria>Diagnosis of idiopathic dilated cardiomyopathy Optimized therapy and for idiopathic dilated cardiomyopathy Left ventricular ejection fraction (Simpson) &lt; 35% Peak oxygen consumption (VO2 peak) &lt; 16 mL.kg1min1 Functional classes IIIV of the NYHA dilated cardiopathies of ischemic or chagasic origin primary valve disease excessive use of alcohol or illicit drugs pregnancy ventricular arrhythmias any comorbidity with impact on survival</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>